Cypress Wealth Services LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 15.6% during the first quarter, Holdings Channel.com reports. The firm owned 19,076 shares of the biopharmaceutical company’s stock after selling 3,517 shares during the period. Cypress Wealth Services LLC’s holdings in Pfizer were worth $529,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Baugh & Associates LLC raised its stake in shares of Pfizer by 34.4% during the first quarter. Baugh & Associates LLC now owns 171,506 shares of the biopharmaceutical company’s stock valued at $4,759,000 after purchasing an additional 43,907 shares in the last quarter. Congress Park Capital LLC raised its stake in shares of Pfizer by 10.2% during the first quarter. Congress Park Capital LLC now owns 21,640 shares of the biopharmaceutical company’s stock valued at $601,000 after purchasing an additional 2,000 shares in the last quarter. Tarbox Family Office Inc. raised its stake in shares of Pfizer by 2.4% during the first quarter. Tarbox Family Office Inc. now owns 29,724 shares of the biopharmaceutical company’s stock valued at $825,000 after purchasing an additional 684 shares in the last quarter. 180 Wealth Advisors LLC raised its stake in shares of Pfizer by 3.1% during the first quarter. 180 Wealth Advisors LLC now owns 28,489 shares of the biopharmaceutical company’s stock valued at $791,000 after purchasing an additional 857 shares in the last quarter. Finally, Stokes Capital Advisors LLC bought a new stake in shares of Pfizer during the first quarter valued at about $203,000. 68.36% of the stock is currently owned by institutional investors.
Pfizer Trading Up 1.4 %
PFE traded up $0.38 during trading on Thursday, reaching $27.80. The company had a trading volume of 27,944,899 shares, compared to its average volume of 40,970,031. The firm’s 50-day simple moving average is $27.81 and its 200 day simple moving average is $27.69. The company has a market cap of $157.53 billion, a price-to-earnings ratio of -458.26, a PEG ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.
Pfizer Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.
Analyst Ratings Changes
Several brokerages have commented on PFE. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $35.86.
Check Out Our Latest Stock Report on Pfizer
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
- Five stocks we like better than Pfizer
- Quiet Period Expirations Explained
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Health Care Stocks Explained: Why You Might Want to Invest
- Progress Software Stock Back in the Green After Beating Forecasts
- How to Most Effectively Use the MarketBeat Earnings Screener
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.